Patents Assigned to NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
-
Patent number: 11851486Abstract: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.Type: GrantFiled: May 1, 2018Date of Patent: December 26, 2023Assignees: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki KaishaInventors: Takako Matsuoka, Manabu Araki, Takashi Yamamura
-
Publication number: 20230405033Abstract: The present invention provides a therapeutic agent for progressive disease caused by an increase in Eomes-positive CD4-positive T cells, comprising a compound represented by formula (I) or a salt thereof as an active ingredient. In the formula, R1 is an aldopyranose residue, R2 is a hydrogen atom or a hydroxy group, R3 is —CH2—, —CH(OH)—CH2—, or —CH?CH—, R4 is a hydrogen atom or CH3, x is 0 to 35, and y and z each are an integer satisfying y+z=0 to 3.Type: ApplicationFiled: November 6, 2020Publication date: December 21, 2023Applicant: National Center of Neurology and PsychiatryInventors: Takashi Yamaura, Shinji Oki, Benjamin Joseph Edward Raveney, Wakiro Sato, Tomoko Okamoto
-
Patent number: 11781140Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: GrantFiled: August 25, 2022Date of Patent: October 10, 2023Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu Honda, Kaname Muchima, Takahiro Fukui, Saki Hasegawa, Shin'ichi Takeda, Yoshitsugu Aoki
-
Publication number: 20230226153Abstract: It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.Type: ApplicationFiled: January 30, 2023Publication date: July 20, 2023Applicant: National Center of Neurology and PsychiatryInventors: Takashi OKADA, Yuko KASAHARA, Shinichi TAKEDA
-
Patent number: 11655472Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: GrantFiled: June 23, 2022Date of Patent: May 23, 2023Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko Enya, Yuta Sunadoi, Reiko Waki, Kaname Muchima, Shin'ichi Takeda, Yoshitsugu Aoki
-
Patent number: 11655493Abstract: A marker for determining a mental disease is provided. The marker can be used in an objective diagnosis of such a mental disease. The marker contains one or more enterobacteria of Bifidobacterium, Lactobacillus, Lactobacillus brevis, Lactobacillus reuteri subgroup, Lactobacillus sakei subgroup, Atopobium cluster, Bacteroides fragilis group, Enterococcus, Clostridium coccoides group, Clostridium leptum subgroup, Staphylococcus, Clostridium perfringens, and Enterobacteriaceae.Type: GrantFiled: April 15, 2016Date of Patent: May 23, 2023Assignees: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, KABUSHIKI KAISHA YAKULT HONSHAInventors: Hiroshi Kunugi, Emiko Aizawa, Hirokazu Tsuji
-
Publication number: 20230151050Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: November 8, 2022Publication date: May 18, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20230140736Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: ApplicationFiled: February 26, 2021Publication date: May 4, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230097387Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.Type: ApplicationFiled: August 25, 2022Publication date: March 30, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yu HONDA, Kaname MUCHIMA, Takahiro FUKUI, Saki HASEGAWA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230073008Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: ApplicationFiled: December 25, 2020Publication date: March 9, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20230045557Abstract: The present specification provides an antisense oligomer capable of causing simultaneous skipping of a plurality of exons in pre-mRNA of interest, and a pharmaceutical composition comprising the oligomer. The present specification also provides an antisense oligomer or a pharmaceutically acceptable salt thereof, or hydrate thereof which causes simultaneous skipping of two or more numerically consecutive exons from pre-mRNA of interest, the antisense oligomer comprising a base sequence complementary to a base sequence of a region including the vicinity of a donor of any intron in the pre-mRNA of interest, or a region including the vicinity of an acceptor of any intron in the pre-mRNA of interest, or a partial base sequence thereof.Type: ApplicationFiled: December 18, 2020Publication date: February 9, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20220333112Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.Type: ApplicationFiled: June 23, 2022Publication date: October 20, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
-
Publication number: 20220162604Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: ApplicationFiled: June 30, 2021Publication date: May 26, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20220127606Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.Type: ApplicationFiled: January 29, 2020Publication date: April 28, 2022Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Takashi Okada, Hiromi KINOH, Yoshitsugu AOKI, Shin'ichi TAKEDA
-
Publication number: 20220049257Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: ApplicationFiled: November 2, 2021Publication date: February 17, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20220047521Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.Type: ApplicationFiled: November 2, 2021Publication date: February 17, 2022Applicant: National Center of Neurology and PsychiatryInventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
-
Patent number: 11191733Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.Type: GrantFiled: February 28, 2017Date of Patent: December 7, 2021Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
-
Patent number: 11193125Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.Type: GrantFiled: August 15, 2017Date of Patent: December 7, 2021Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 11174317Abstract: The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an IL-6 inhibitor as an active ingredient.Type: GrantFiled: June 3, 2016Date of Patent: November 16, 2021Assignees: National Center of Neurology and Psychiatry, Chugai Seiyaku Kabushiki KaishaInventors: Hiroshi Kunugi, Chisato Wakabayashi
-
Publication number: 20210340171Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: July 14, 2021Publication date: November 4, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA